Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Diabetes Mellitus, Type 2 1Dementia 1Cognitive Dysfunction 1

Interventions

Cyclophosphamide 342Rituximab 304Vincristine 157Doxorubicin 154venetoclax 153fludarabine 153Specimen Handling 152Prednisone 150Biopsy 122Magnetic Resonance Spectroscopy 117obinutuzumab 116Lenalidomide 109Dexamethasone 104Cytarabine 97ibrutinib 95Etoposide 92fludarabine phosphate 87Methotrexate 84acalabrutinib 78Bendamustine Hydrochloride 72zanubrutinib 71blinatumomab 63pembrolizumab 62CT-P10 60Gemcitabine 51Nivolumab 45glofitamab 44Calcium Dobesilate 44Mercaptopurine 43prednylidene 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
mazdutide × Lymphoid × 1 year × Clear all
NCT07083154 2026-03-05

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 3 Recruiting
420 enrolled
Lymphoid

Dementia, Diabetes Mellitus, Type 2, Lymphoma, Follicular, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡